Results 31 to 40 of about 4,916 (258)

Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series

Medicina, 2023
Background and Objectives: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact.
Atsuhiro Kitaura, Hiroatsu Sakamoto, Shinichi Hamasaki, Shota Tsukimoto, Yasufumi Nakajima   +4 more
doaj   +1 more source

A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation

Clinical and Translational Science, 2021
The clinical effects of remimazolam (an investigational, ultra‐short acting benzodiazepine being studied in procedural sedation) were measured using the Modified Observer’s Assessment of Awareness/Sedation Scale (MOAA/S).
Jie Zhou, Laura Curd, Lauren R. L. Lohmer, Natalie Delpratt, Joachim Ossig, Frank Schippers, Thomas Stoehr, Virginia D. Schmith   +7 more
doaj   +1 more source

Intraoperative responses of motor evoked potentials to the novel intravenous anesthetic remimazolam during spine surgery: a report of two cases

JA Clinical Reports, 2020
Background Remimazolam is a novel short-acting benzodiazepine characterized by metabolism independent from organ function. We report intraoperative MEP responses of two patients who underwent spine surgery under general anesthesia using remimazolam. Case
Takashi Kondo, Yukari Toyota, Soshi Narasaki, Tomoyuki Watanabe, Hirotsugu Miyoshi, Noboru Saeki, Yasuo M. Tsutsumi   +6 more
doaj   +1 more source

Effects of remimazolam and propofol on sleep rhythm and delirium after spinal surgery in elderly patients

Perioperative Medicine
This study aims to investigate the effects of remimazolam on postoperative melatonin secretion, sleep rhythm, and postoperative delirium (POD) in elderly patients undergoing spinal surgery.
Ya-Qiu Li, Heng Zhou, Rui-Min Wu, Wang Xuri   +3 more
semanticscholar   +1 more source

Remimazolam: Patient satisfaction and safety for procedural sedation [PDF]

, 2023
Remimazolam je novi intravenski anestetik iz skupine benzodiazepina. Molekularna struktura remimazolama omogućuje mu poseban farmakokinetički profil te ga izdvaja od drugih lijekova u istoj skupini.
Kovač, Nataša, Vučić, Marinko, Ožegić, Ognjen, Bodulica, Bruna, Pažur, Iva, Radočaj, Tomislav, Škrtić, Matteo, Lijović, Lada, Periša, Nikola   +8 more
core   +1 more source

Relationship between age and remimazolam dose required for inducing loss of consciousness in older surgical patients

Frontiers in Medicine
BackgroundRemimazolam is a new ultra-short-acting benzodiazepine for procedural sedation and general anaesthesia, characterised by rapid onset of action, quick recovery, and organ-independent metabolism.
Jin-Chao Song, Xiao-xi Wang, Xiang Fu, Wei Chen, Shu-heng Tang, Fang Deng, Hua Yang, Wen Liu   +7 more
doaj   +1 more source

Remimazolam: What Is It?

, 2023
Remimazolam (CNS 7056) is a new rapidly metabolized benzodiazepine and has been presented in clinical research protocols. It is water-soluble and when diluted into a solution becomes a painless injectate.
Amornyotin, Somchai
core   +1 more source

ED50 and ED95 of remimazolam for loss of consciousness in young children.

British Journal of Anaesthesia
BACKGROUND The optimal single i.v. bolus dose of remimazolam for induction of general anaesthesia in children is not defined. We aimed to determine the 50% (ED50) and 95% (ED95) effective doses of remimazolam for inducing loss of consciousness in ...
Yu-Hang Cai, Le-Qi Dong, John W. Zhong, Zheng Lin, Cong-De Chen, Libin Zhu, Xiao-Kun Lin, Peter Szmuk, Hua-Cheng Liu   +8 more
semanticscholar   +1 more source

Remimazolam – current status, opportunities and challenges [PDF]

, 2023
The short acting benzodiazepine remimazolam has been well characterised for use during procedural sedation. Onset of hypnotic effect is swifter than midazolam and recovery is faster with a period of antegrade amnesia. Haemodynamic changes associated with
Sneyd, J. Robert
core   +1 more source

Remimazolam Suppresses Oxidative Stress and Apoptosis in Cerebral Ischemia/Reperfusion Injury by Regulating AKT/GSK-3β/NRF2 Pathway

Drug Design, Development and Therapy
Introduction The mechanism of remimazolam, a benzodiazepine that activates γ-aminobutyric acid a (GABAa) receptors, in cerebral ischemia/reperfusion (I/R) injury is not well understood.
Mei Duan, Ning Yu, Jia Liu, Yang Zhao, Jing Zhang, Siyi Song, Shilei Wang   +6 more
semanticscholar   +1 more source